CompletedPhase 3NCT02685709
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Studying Acromegaly
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chiasma, Inc.
- Principal Investigator
- Maria Fleseriu, M.D., FACENorthwest Pituitary Center, Oregon Health & Science University , Portland, OR, USA
- Intervention
- Octreotide capsules(drug)
- Enrollment
- 146 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2016 – 2021
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Keck Medical Center of University of Southern California, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- Emory University, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Rutgers - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
- Columbia University Medical Center, New York, New York, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02685709 on ClinicalTrials.govOther trials for Acromegaly
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06930625A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsDebiopharm International SA
- RECRUITINGPHASE2NCT07037420ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07179926Effects of Pasireotide Lar Therapy on Bone MetabolismFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE1NCT07195175Study of MAR002 in Healthy MenMarea Therapeutics
- RECRUITINGNCT06597383The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In AcromegalyIRCCS San Raffaele
- RECRUITINGNANCT06949891KETOgenic Diet Therapy in Patients With ACROmegalyErasmus Medical Center
- RECRUITINGNCT06344650Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.IRCCS San Raffaele
- RECRUITINGNCT05131100Korean Regulatory Post Marketing Surveillance for SomavertPfizer